Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling.

The structural basis for the cooperativity of diazepam oxidation catalyzed by human cytochrome P450 3A4 (CYP3A4) and 40 mutants has been investigated. An ordered two-site model in which substrates bind first to a catalytic/effector site and then to the catalytic site was used to explain sigmoidal kinetics for temazepam formation but hyperbolic kinetics for nordiazepam formation. In this model diazepam binds to the enzyme-substrate complex with a greater affinity (K(S2)=140 microM) than to free enzyme (K(S1)=960 microM). Residues 107, 119, 211, 301, 304, 309, 369, 370, and 373 play an important role in determining regioselectivity of diazepam oxidation. Interestingly, S119F and A370F displayed sigmoidal kinetics for nordiazepam formation, whereas I301F exhibited hyperbolic kinetics for both products. In the presence of increasing concentrations of testosterone, K(S1) for diazepam decreased, whereas K(S2) increased. The data suggest that three sites exist within the active pocket.

[1]  A. P. Koley,et al.  Differential Mechanisms of Cytochrome P450 Inhibition and Activation by α-Naphthoflavone* , 1997, The Journal of Biological Chemistry.

[2]  Ortiz de Montellano,et al.  Cytochrome P-450: Structure, Mechanism, and Biochemistry , 1986 .

[3]  H. Klenk,et al.  Identification and functional characterization of eight CYP3A4 protein variants. , 2001, Pharmacogenetics.

[4]  M. Sutcliffe,et al.  Amino acid 305 determines catalytic center accessibility in CYP3A4. , 2000, Biochemistry.

[5]  A. Li,et al.  Substrates of human hepatic cytochrome P450 3A4. , 1995, Toxicology.

[6]  K. Korzekwa,et al.  Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.

[7]  Renke Dai,et al.  Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site , 1999 .

[8]  E. Johnson,et al.  Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone. , 1988, Molecular pharmacology.

[9]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[10]  J. Halpert,et al.  Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. , 2002, Molecular pharmacology.

[11]  A. Y. Lu,et al.  Allosteric behavior in cytochrome p450-dependent in vitro drug-drug interactions: a prospective based on conformational dynamics. , 2001, Chemical research in toxicology.

[12]  J. Halpert,et al.  Use of the steroid derivative RPR 106541 in combination with site-directed mutagenesis for enhanced cytochrome P-450 3A4 structure/function analysis. , 1999, The Journal of pharmacology and experimental therapeutics.

[13]  J. Halpert,et al.  Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. , 2001, Biochemistry.

[14]  A. Rettie,et al.  Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.

[15]  I. H. Segel.  Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems , 1975 .

[16]  M. Huang,et al.  In vitro and in vivo activation of oxidative drug metabolism by flavonoids. , 1984, The Journal of pharmacology and experimental therapeutics.

[17]  J. Halpert,et al.  Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D E McRee,et al.  Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. , 2000, Molecular cell.

[19]  L. Wienkers,et al.  Topological alteration of the CYP3A4 active site by the divalent cation Mg(2+). , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[20]  T. Baillie,et al.  Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. , 1999, The Biochemical journal.

[21]  J. Halpert,et al.  Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis. , 2001, Current drug metabolism.

[22]  J. Liu,et al.  Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and alpha-naphthoflavone stimulation. , 1998, Archives of biochemistry and biophysics.

[23]  B. Ring,et al.  Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. , 1998, Pharmacogenetics.

[24]  J. Miners,et al.  Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. , 1994, British journal of clinical pharmacology.

[25]  J. Houston,et al.  Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[26]  J. Halpert,et al.  Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity. , 2000, The Journal of pharmacology and experimental therapeutics.

[27]  G. Miller,et al.  Elucidation of distinct ligand binding sites for cytochrome P450 3A4. , 2000, Biochemistry.